IPF Clinical Trial Tracker — Idiopathic Pulmonary Fibrosis Trial Intelligence 2026

Why IPF trial monitoring matters

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible fibrotic lung disease characterized by relentless decline in lung function, with a median survival of 3–5 years from diagnosis. Approximately 50,000 new cases are diagnosed annually in the US, with global incidence estimated at 3–9 per 100,000. The disease is defined by usual interstitial pneumonia (UIP) pathology — a histologic pattern of temporal and spatial heterogeneity driven by aberrant fibroblast activation, extracellular matrix deposition, and alveolar epithelial injury — with no identified causal mechanism, making the "idiopathic" designation clinically accurate and therapeutically challenging.

The treatment landscape was transformed by the approvals of pirfenidone (Esbriet, Roche/Genentech) and nintedanib (Ofev, Boehringer Ingelheim) in 2014, each of which slows FVC decline by approximately 50% relative to placebo but does not halt or reverse disease progression. With approximately 45 recruiting IPF trials currently registered on ClinicalTrials.gov, the field is actively seeking disease-modifying agents capable of genuine stabilization or reversal. Key signals to monitor include:

• TGF-beta pathway agents — including novel receptor antagonists and downstream signaling inhibitors targeting the central driver of fibroblast activation
• Lysophosphatidic acid receptor 1 (LPAR1) antagonists — BMS-986020 (Bristol-Myers Squibb) and follow-on programs addressing fibroblast chemotaxis
• Integrin inhibitors — particularly alpha-v integrin programs targeting TGF-beta activation at the cell surface
• FGFR inhibitor combinations with existing antifibrotics, exploiting FGFR pathway upregulation in IPF fibroblasts
• Combination antifibrotic strategies pairing nintedanib or pirfenidone with novel mechanism agents
• Autotaxin inhibitors addressing the lysophosphatidic acid biosynthetic pathway upstream of LPAR1
• Lung transplant and patient-reported outcome endpoint trials addressing quality of life and functional status

What we monitor for IPF

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For an IPF watch profile, you can configure:

• Condition keywords: "idiopathic pulmonary fibrosis", "IPF", "usual interstitial pneumonia", "UIP", "interstitial lung disease", "pulmonary fibrosis"
• Intervention keywords: "nintedanib", "pirfenidone", "TGF-beta", "LPAR1", "BMS-986020", "integrin", "autotaxin", "FGFR", "antifibrotic", "lysophosphatidic acid"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

The IPF treatment landscape in 2026

Approved antifibrotics: nintedanib and pirfenidone as the standard-of-care baseline

Nintedanib (Ofev, Boehringer Ingelheim) is a small-molecule tyrosine kinase inhibitor targeting VEGFR, FGFR, and PDGFR signaling pathways. Its approval was supported by the INPULSIS-1 and INPULSIS-2 trials (NCT01335464, NCT01335477), which demonstrated a reduction in annual FVC decline from approximately 239 mL/year to 114 mL/year — roughly 52% slowing of lung function loss. Pirfenidone (Esbriet, Roche/Genentech) — a small molecule with anti-inflammatory, antifibrotic, and antioxidant properties through incompletely characterized mechanisms — was supported by the CAPACITY trials (NCT00287716, NCT00287729) and the ASCEND trial (NCT01366209), which demonstrated similar magnitude of FVC preservation. Both agents are now standard of care, and virtually all Phase 2 and Phase 3 trials of novel agents are conducted on background antifibrotic therapy or in combination designs. The critical unmet need is not a replacement for these agents but a treatment that provides additional benefit on top of them — or reverses rather than merely slows disease.

TGF-beta pathway: the central fibrotic target

Transforming growth factor beta (TGF-beta) is the dominant pro-fibrotic cytokine in IPF, driving fibroblast-to-myofibroblast differentiation, extracellular matrix production, and epithelial-mesenchymal transition. Despite its central importance, TGF-beta pathway inhibition has proven challenging — systemic TGF-beta blockade carries significant immunosuppressive and inflammatory risks, and early trials of pan-TGF-beta antibodies produced adverse events including skin and mucosal toxicity. The development focus has shifted to pathway-selective approaches: inhibitors of specific TGF-beta receptor subunits, downstream SMAD signaling components, and integrin-mediated TGF-beta activation. Bintrafusp alfa (M7824, Merck KGaA) — a bifunctional fusion protein targeting both TGF-beta and PD-L1 — has been evaluated across fibrotic indications. The ATLAS trial (NCT03042975) examined pamrevlumab (FG-3019, FibroGen), a human monoclonal antibody targeting connective tissue growth factor (CTGF/CCN2), a downstream TGF-beta effector — the program has demonstrated signals of FVC preservation in Phase 3. Monitoring TGF-beta pathway trial registrations requires tracking both upstream receptor programs and downstream effector strategies.

LPAR1 antagonists: lysophosphatidic acid pathway inhibition

Lysophosphatidic acid (LPA) signaling through the LPAR1 receptor promotes fibroblast migration, proliferation, and survival — making LPAR1 antagonism a mechanistically rational antifibrotic strategy. BMS-986020 (Bristol-Myers Squibb) was one of the most closely watched Phase 2 programs in IPF, evaluated in NCT01766817. While the trial demonstrated FVC preservation trends, the program's advancement was complicated by hepatotoxicity signals observed with BMS-986020 and led to discontinuation of further development of that specific compound. The LPAR1 target itself remains scientifically validated, and follow-on programs with improved hepatic safety profiles — including GLPG1690 (ziritaxestat, Galapagos/AbbVie) and successor molecules — have continued. The autotaxin enzyme, which synthesizes LPA from lysophosphatidylcholine, represents an upstream target: GLPG1690 (an autotaxin inhibitor) was evaluated in ISABELA trials (NCT03711162, NCT03733444) but did not meet primary endpoints in Phase 3. Monitoring LPAR1 and autotaxin program registrations requires distinguishing between the validated mechanism and the specific development challenges of individual compounds.

Integrin inhibitors: targeting TGF-beta activation at the cell surface

Alpha-v integrins (particularly alpha-v beta-6 and alpha-v beta-8) expressed on alveolar epithelial cells serve as the primary activators of latent TGF-beta in the lung — making integrin inhibition a mechanism for blocking TGF-beta activity at its point of local activation rather than globally. Bexotegrast (PLN-74809, Pliant Therapeutics) is a dual alpha-v beta-6 / alpha-v beta-8 integrin inhibitor that has entered Phase 2b in IPF (BEACON-IPF, NCT04396756), with interim data showing dose-dependent reduction in FVC decline. This represents one of the most mechanistically precise approaches in the pipeline: blocking integrin-mediated TGF-beta activation specifically in the fibrotic lung while potentially sparing systemic TGF-beta signaling. Abituzumab (EMD 525797, Merck KGaA) and other pan-alpha-v integrin antibodies have explored broader integrin targeting. The integrin program space requires close monitoring as Phase 2b data from multiple programs are expected in 2026–2027.

FGFR inhibitors and kinase combinations

Fibroblast growth factor receptor (FGFR) signaling is upregulated in IPF lung tissue and contributes to fibroblast proliferation and resistance to apoptosis. Nintedanib's mechanism includes FGFR inhibition, but the relative contribution of each kinase target to its clinical effect is not fully characterized. Dedicated FGFR inhibitor programs — including those originally developed in oncology that have entered fibrosis-specific development — are being evaluated as add-on therapies to background antifibrotic treatment. FGFR inhibitor combinations with nintedanib carry overlapping kinase inhibition profiles that require careful tolerability assessment. Monitoring FGFR program registrations in IPF provides intelligence on whether oncology-derived kinase inhibitor platforms are expanding into fibrotic indications — a pattern with implications for both development strategy and potential combination partner selection.

Combination antifibrotic strategies and novel mechanism pairing

The prevailing hypothesis guiding IPF trial design is that targeting multiple distinct fibrotic pathways simultaneously will achieve greater efficacy than any single agent alone. Trial designs increasingly pair approved antifibrotics (nintedanib or pirfenidone) with novel mechanism agents in the background therapy arm. Key combination questions include: whether TGF-beta pathway inhibition and kinase inhibition are synergistic or merely additive; whether integrin inhibition adds meaningfully to LPAR1 antagonism; and whether any combination achieves FVC stabilization or reversal rather than slowed decline. Phase 2 biomarker-rich designs are increasingly using circulating KL-6, SP-D, CA-19-9, and MMP-7 as pharmacodynamic endpoints to characterize mechanism engagement before committing to FVC-based Phase 3 programs.

Patient-reported outcomes and lung transplant research

FVC decline has been the regulatory standard primary endpoint for IPF trials since the CAPACITY and INPULSIS programs established its validity as a surrogate for survival and disease progression. However, regulatory agencies and patient advocacy groups have emphasized the importance of patient-reported outcomes — dyspnea burden, cough frequency, exercise tolerance, and health-related quality of life — as co-primary or key secondary endpoints. The Living with IPF (L-IPF) questionnaire and UCSD Shortness of Breath Questionnaire are increasingly embedded in trial designs. Separately, lung transplantation — the only intervention that substantially extends life in advanced IPF — is the subject of dedicated registry and surgical optimization research, with trials evaluating bridge-to-transplant strategies, organ preservation techniques, and post-transplant management. Monitoring patient-reported outcome and transplant program registrations completes a comprehensive IPF trial intelligence picture.

Who uses IPF trial monitoring

Pulmonologists and ILD specialists at academic centers

Pulmonologists specializing in interstitial lung disease at NCI-designated centers and academic medical institutions track new trial registrations to identify patient referral opportunities, evaluate combination therapy eligibility criteria, and stay current on the evolving antifibrotic combination landscape. With approximately 45 recruiting IPF trials active at any given time, systematic monitoring identifies new programs before they appear in conference abstracts or journal publications. ILD multidisciplinary teams increasingly rely on current trial landscape knowledge to inform sequencing decisions for patients progressing on background nintedanib or pirfenidone.

Pharma and biotech BD teams in the respiratory fibrosis space

Business development teams at Boehringer Ingelheim, Roche/Genentech, Bristol-Myers Squibb, Galapagos, Pliant Therapeutics, FibroGen, and emerging antifibrotic biotechs track competitor trial registrations to inform partnership strategy, combination partner identification, and indication prioritization. A new Phase 1 registration for an integrin inhibitor or TGF-beta receptor antagonist in IPF may precede public clinical readout by 24–36 months. Given the validated but narrow clinical endpoint space — FVC decline as a surrogate — mechanism differentiation and combination compatibility assessment are high-priority BD intelligence needs.

Respiratory disease investors

Investors with exposure to IPF platform companies — antifibrotic biotechs, kinase inhibitor platforms, and antibody-based approaches — track IPF trial activity as a leading indicator of clinical strategy and data catalyst timing. Phase 2b enrollment completion signals potential pivotal data in 18–24 months. Protocol amendments revealing FVC endpoint strategy changes, dose selection decisions, or background therapy requirements can be meaningful signals. Given the small number of active Phase 2b and Phase 3 programs, individual trial registrations and amendments carry higher information density than in larger indications with broader pipelines.

Frequently asked questions

Can I track IPF separately from other interstitial lung diseases like scleroderma-ILD or unclassifiable ILD?

Yes. On the Pro plan ($149/month), you can create separate profiles for IPF-specific trials (keywords: "idiopathic pulmonary fibrosis", "IPF", "usual interstitial pneumonia") and for broader ILD programs (keywords: "interstitial lung disease", "fibrotic ILD", "progressive fibrosing ILD"). Nintedanib received a label expansion to systemic sclerosis-associated ILD and other fibrosing ILDs — monitoring broader ILD trial registrations captures combination and label-expansion programs relevant to IPF pipeline assessment.

Does this capture biomarker and companion diagnostic studies alongside therapeutic trials?

Yes. ClinicalTrials.gov registers biomarker qualification studies, natural history studies, and companion diagnostic co-development protocols alongside therapeutic interventional trials. Configuring your profile to include terms like "KL-6", "MMP-7", "SP-D", "IPF biomarker", or "ILD registry" will capture non-interventional studies that provide important context for interpreting therapeutic trial results. Biomarker studies often register 6–12 months ahead of Phase 2 programs they support — early registration provides a leading indicator of upcoming therapeutic program activity.

How is this different from manually searching ClinicalTrials.gov for IPF trials?

ClinicalTrials.gov requires manual searches with no structured alerting for new registrations or status updates. In a field with approximately 45 active IPF trials and complex multi-mechanism combination designs, manually tracking protocol amendments — dose cohort additions, background therapy requirement changes, secondary endpoint modifications — is time-intensive and error-prone. DataLookout delivers a filtered digest to your inbox each morning covering new registrations, status transitions, and protocol updates, so you maintain comprehensive IPF trial awareness without daily manual search effort.